Skip to main content
Top
Published in: Clinical and Translational Oncology 2/2018

01-02-2018 | Research Article

Treatment strategies for rectal cancer with synchronous liver metastases: surgical and oncological outcomes with propensity-score analysis

Authors: H. Salvador-Rosés, S. López-Ben, P. Planellas, E. Canals, M. Casellas-Robert, R. Farrés, E. Ramos, A. Codina-Cazador, J. Figueras

Published in: Clinical and Translational Oncology | Issue 2/2018

Login to get access

Abstract

Background

The optimal sequence of surgery for rectal cancer (RC) with synchronous liver metastases (SLM) is controversial.

Objectives

The primary objective was to explore differences between the rectum first (RF) and the liver first strategy (LF) to achieve the complete resection (CR) of both tumors.

Methods

Patients diagnosed of RC with resectable or potentially resectable SLM were included. Data collected prospectively were analyzed with an intention-to-treat perspective, adjusting for between-sample differences (propensity score). The complete resection rate (CRR) was the main outcome variable.

Results

During a 5-year period, 23 patients underwent the LF strategy and 24 patients the RF strategy. Median overall survival (OS) was 32 months in the LF group and 41 months in the RF group (p = 0.499), and was 51 and 17 months, respectively, for patients achieving or not achieving CR of both tumors (p < 0.001). CRR’s were 65% in liver first group and 63% in rectum first group, (p = 0.846). No between-strategy differences in morbidity or duration of treatment were observed.

Conclusions

This study supports the notion that the achievement of CR of RC and SLM should be the goal of oncological treatment. Both RF and LF strategies are feasible and safe, but no between-strategy differences have been found in the CRR.
Literature
1.
go back to reference Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.CrossRefPubMed
2.
go back to reference Van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32:457–65.CrossRefPubMed Van der Geest LG, Lam-Boer J, Koopman M, Verhoef C, Elferink MA, de Wilt JH. Nationwide trends in incidence, treatment and survival of colorectal cancer patients with synchronous metastases. Clin Exp Metastasis. 2015;32:457–65.CrossRefPubMed
3.
go back to reference Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.CrossRefPubMedPubMedCentral Choti MA, Sitzmann JV, Tiburi MF, Sumetchotimetha W, Rangsin R, Schulick RD, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.CrossRefPubMedPubMedCentral
4.
go back to reference Elferink MA, van Steenbergen LN, Krijnen P, Lemmens VE, Rutten HJ, Marijnen CA, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer. 2010;46:1421–9.CrossRefPubMed Elferink MA, van Steenbergen LN, Krijnen P, Lemmens VE, Rutten HJ, Marijnen CA, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer. 2010;46:1421–9.CrossRefPubMed
5.
go back to reference Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25 (discussion 25–7).CrossRefPubMedPubMedCentral Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25 (discussion 25–7).CrossRefPubMedPubMedCentral
6.
go back to reference van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14:56–61.CrossRefPubMed van der Pool AE, Damhuis RA, Ijzermans JN, de Wilt JH, Eggermont AM, Kranse R, et al. Trends in incidence, treatment and survival of patients with stage IV colorectal cancer: a population-based series. Colorectal Dis. 2012;14:56–61.CrossRefPubMed
7.
go back to reference Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872–8.CrossRefPubMed Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. Br J Surg. 2006;93:872–8.CrossRefPubMed
8.
go back to reference Mentha G, Majno P, Terraz S, Rubbia-Brandt L, Gervaz P, Andres A, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33(Suppl 2):S76–83.CrossRefPubMed Mentha G, Majno P, Terraz S, Rubbia-Brandt L, Gervaz P, Andres A, et al. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol. 2007;33(Suppl 2):S76–83.CrossRefPubMed
9.
go back to reference Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481–91.CrossRefPubMed Reddy SK, Pawlik TM, Zorzi D, Gleisner AL, Ribero D, Assumpcao L, et al. Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis. Ann Surg Oncol. 2007;14:3481–91.CrossRefPubMed
10.
go back to reference Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.CrossRefPubMed Brouquet A, Mortenson MM, Vauthey JN, Rodriguez-Bigas MA, Overman MJ, Chang GJ, et al. Surgical strategies for synchronous colorectal liver metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg. 2010;210:934–41.CrossRefPubMed
11.
go back to reference Andres A, Mentha G, Adam R, Gerstel E, Skipenko OG, Barroso E, et al. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg. 2015;102:691–9.CrossRefPubMed Andres A, Mentha G, Adam R, Gerstel E, Skipenko OG, Barroso E, et al. Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases. Br J Surg. 2015;102:691–9.CrossRefPubMed
12.
go back to reference Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003;90:956–62.CrossRefPubMed Weber JC, Bachellier P, Oussoultzoglou E, Jaeck D. Simultaneous resection of colorectal primary tumour and synchronous liver metastases. Br J Surg. 2003;90:956–62.CrossRefPubMed
13.
go back to reference Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg. 2013;216:707–16.CrossRefPubMedPubMedCentral Mayo SC, Pulitano C, Marques H, Lamelas J, Wolfgang CL, de Saussure W, et al. Surgical management of patients with synchronous colorectal liver metastasis: a multicenter international analysis. J Am Coll Surg. 2013;216:707–16.CrossRefPubMedPubMedCentral
14.
go back to reference Sabbagh C, Cosse C, Ravololoniaina T, Chauffert B, Joly JP, Mauvais F, et al. Oncological strategies for middle and low rectal cancer with synchronous liver metastases. Int J Surg. 2015;23(Pt A):186–93.CrossRefPubMed Sabbagh C, Cosse C, Ravololoniaina T, Chauffert B, Joly JP, Mauvais F, et al. Oncological strategies for middle and low rectal cancer with synchronous liver metastases. Int J Surg. 2015;23(Pt A):186–93.CrossRefPubMed
15.
go back to reference van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg. 2010;97:383–90.CrossRefPubMed van der Pool AE, de Wilt JH, Lalmahomed ZS, Eggermont AM, Ijzermans JN, Verhoef C. Optimizing the outcome of surgery in patients with rectal cancer and synchronous liver metastases. Br J Surg. 2010;97:383–90.CrossRefPubMed
16.
go back to reference Norstein J, Silen W. Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg. 1997;1:398–407.CrossRefPubMed Norstein J, Silen W. Natural history of liver metastases from colorectal carcinoma. J Gastrointest Surg. 1997;1:398–407.CrossRefPubMed
17.
go back to reference Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–8.CrossRefPubMed Charnsangavej C, Clary B, Fong Y, Grothey A, Pawlik TM, Choti MA. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13:1261–8.CrossRefPubMed
18.
go back to reference Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.CrossRefPubMedPubMedCentral Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist. 2012;17:1225–39.CrossRefPubMedPubMedCentral
19.
go back to reference Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden OJ, Lau WY, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford). 2000;2:333–9.CrossRef Strasberg SM, Belghiti J, Clavien PA, Gadzijev E, Garden OJ, Lau WY, et al. The Brisbane 2000 terminology of liver anatomy and resections. HPB (Oxford). 2000;2:333–9.CrossRef
20.
go back to reference Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
21.
go back to reference Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMed Rahbari NN, Garden OJ, Padbury R, Brooke-Smith M, Crawford M, Adam R, et al. Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery. 2011;149:713–24.CrossRefPubMed
22.
go back to reference Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149:680–8.CrossRefPubMed Koch M, Garden OJ, Padbury R, Rahbari NN, Adam R, Capussotti L, et al. Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery. 2011;149:680–8.CrossRefPubMed
23.
go back to reference Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, et al. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford). 2011;13:528–35.CrossRef Rahbari NN, Garden OJ, Padbury R, Maddern G, Koch M, Hugh TJ, et al. Post-hepatectomy haemorrhage: a definition and grading by the International Study Group of Liver Surgery (ISGLS). HPB (Oxford). 2011;13:528–35.CrossRef
24.
go back to reference Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH. The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. 2009;52:23–30.CrossRefPubMed Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH. The “liver-first approach” for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum. 2009;52:23–30.CrossRefPubMed
25.
go back to reference Vigano L, Karoui M, Ferrero A, Tayar C, Cherqui D, Capussotti L. Locally advanced mid/low rectal cancer with synchronous liver metastases. World J Surg. 2011;35:2788–95.CrossRefPubMed Vigano L, Karoui M, Ferrero A, Tayar C, Cherqui D, Capussotti L. Locally advanced mid/low rectal cancer with synchronous liver metastases. World J Surg. 2011;35:2788–95.CrossRefPubMed
26.
go back to reference Buchs NC, Ris F, Majno PE, Andres A, Cacheux W, Gervaz P, et al. Rectal outcomes after a liver-first treatment of patients with stage IV rectal cancer. Ann Surg Oncol. 2015;22:931–7.CrossRefPubMed Buchs NC, Ris F, Majno PE, Andres A, Cacheux W, Gervaz P, et al. Rectal outcomes after a liver-first treatment of patients with stage IV rectal cancer. Ann Surg Oncol. 2015;22:931–7.CrossRefPubMed
27.
go back to reference Welsh FK, Chandrakumaran K, John TG, Cresswell AB, Rees M. Propensity score-matched outcomes analysis of the liver-first approach for synchronous colorectal liver metastases. Br J Surg. 2016;103:600–6.CrossRefPubMed Welsh FK, Chandrakumaran K, John TG, Cresswell AB, Rees M. Propensity score-matched outcomes analysis of the liver-first approach for synchronous colorectal liver metastases. Br J Surg. 2016;103:600–6.CrossRefPubMed
28.
go back to reference de Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford). 2011;13:745–52.CrossRefPubMedPubMedCentral de Jong MC, van Dam RM, Maas M, Bemelmans MH, Olde Damink SW, Beets GL, et al. The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford). 2011;13:745–52.CrossRefPubMedPubMedCentral
29.
go back to reference Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41:729–41.CrossRefPubMed Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, et al. Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. Cancer Treat Rev. 2015;41:729–41.CrossRefPubMed
30.
go back to reference de Campos-Lobato LF, Stocchi L, de Sousa JB, Buta M, Lavery IC, Fazio VW, et al. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! Ann Surg Oncol. 2013;20:3398–406.CrossRefPubMed de Campos-Lobato LF, Stocchi L, de Sousa JB, Buta M, Lavery IC, Fazio VW, et al. Less than 12 nodes in the surgical specimen after total mesorectal excision following neoadjuvant chemoradiation: it means more than you think! Ann Surg Oncol. 2013;20:3398–406.CrossRefPubMed
Metadata
Title
Treatment strategies for rectal cancer with synchronous liver metastases: surgical and oncological outcomes with propensity-score analysis
Authors
H. Salvador-Rosés
S. López-Ben
P. Planellas
E. Canals
M. Casellas-Robert
R. Farrés
E. Ramos
A. Codina-Cazador
J. Figueras
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 2/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1712-4

Other articles of this Issue 2/2018

Clinical and Translational Oncology 2/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine